Chapter 81

Anti-IgE in Persistent Severe Allergic Asthma

Marc Humbert

Marc Humbert

Professor of Respiratory Medicine

Université Paris-Sud II, Service de Pneumologie Respiratoire, Hôpital Antoine-Béclère, Clamart, France

Search for more papers by this author
Stephen T. Holgate

Stephen T. Holgate

Allergy & Inflammation Research, Division of Infection, Inflammation & Repair School of Medicine, Southampton General Hospital, Southampton, UK

Search for more papers by this author
Howard Fox

Howard Fox

Novartis Horsham Research Centre, Horsham, West Sussex, UK

Search for more papers by this author
Jean Bousquet MD, PhD

Jean Bousquet MD, PhD

CHU Montpellier, Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France

Search for more papers by this author
First published: 25 July 2008

Summary

This chapter contains sections titled:

  • Introduction

  • Burden of severe asthma

  • Treatment options for severe persistent asthma

  • Omalizumab in the treatment of severe persistent allergic asthma

  • Safety and tolerability

  • Selection of patients for omalizumab treatment

  • Future direction

  • Conclusions

  • References

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.